Sinclair Forehead augumentation using Ellanse shows long lasting effects
Forehead augmentation using Ellansé, a polycaprolactone-based derma filler from Sinclair Pharma, has safe, long-lasting cosmetic efficacy, according to a study published in Dermatologic Surgery. Researchers studied 58 patients between October 2013 and October 2015 in a clinic in Seoul, South Korea. The researchers said the study showed Ellansé is a "good option for soft tissue of the forehead."

Save

This article is more than 5 years old. Information may no longer be current.

Polycaprolactone-based dermal filler shows efficacy in forehead augmentation

Source/Disclosures Published by: Source: Bae B, et al. Dermatol Surg. 2016;doi:10.1097/DSS.0000000000000913. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on . Please provide your email address to receive an email when new articles are posted on Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts



Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.



Back to Healio

Polycaprolactone-based dermal filler had long-lasting cosmetic efficacy as soft tissue augmentation of the forehead, according to study results published in Dermatologic Surgery. Researchers studied 58 patients (57 women; age range, 20-65 years) who were undergoing forehead augmentation using Ellansé (polycaprolactone-based dermal filler, Sinclair Pharma) between October 2013 and October 2015 at a dermatology clinic in Seoul, South Korea.

An uneven contour, or a concavity due to a prominent brow rise and relative frontal bone bossing, a flat surface and volume augmentation were reasons for the treatment.

Efficacy at 1, 3, 6, 12 and 24 months postoperatively was measured by Global Aesthetic Improvement Scale (GAIS), which ranged from –1 for worse to 3 for very much improved.

There was an improved outcome in the GAIS score at all posttreatment time points, with mean GAIS score of 2.14 ± 0.95 at 1 month, 2.38 ± 0.77 at 3 months, 2.5 ± 0.76 at 6 months, 2.45 ± 0.52 at 12 months and 2.33 ± 0.5 at 24 months.

“The scores increased markedly from 1 to 3 months and were maintained at 24 months,” the researchers wrote.

Touch-up treatment was performed in three patients after the initial treatment because of insufficient volume.

There were no serious adverse events reported, and reported injection-related adverse events, including edema and ecchymosis, resolved without interventions.

“This study shows that [polycaprolactone-based] dermal filler is a good option for soft tissue augmentation of the forehead, as it is safe and has long-lasting favorable cosmetic efficacy,” the researchers concluded. “Since our study is a preliminary study limited by the lack of a placebo control or blind evaluation by the investigators, further study is needed.” – by Bruce Thiel

Disclosure: The researchers report no relevant financial disclosures.